Prevalence of HTLV-I virus in blood donors and transfusion in Mali: Implications for blood safety

Diarra, Amadou; Kouriba, Bourèma; Guindo, Aldiouma; Maïga, Almoustapha Issiaka; Diabaté, D T; Douyon, I.; Diawara, Sory Ibrahim; Touré, Boubacari Ali; Fonkoro, S.; Murphy, Edward L.; Diallo, Dapa A.

doi:10.1016/j.tracli.2014.05.002

Cited by 10 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These observations highlighted the importance of adding HTLV‐1/2 screening in Benin blood banks to prevent the transfusion of contaminated blood with HTLV infection to recipients. The seroprevalence found in our study is relatively high in comparison to a study conducted among blood donors in nearby West African countries like Senegal, with a prevalence of 0·16%, but low in comparison to studies carried out in Nigeria and Mali that reported a seroprevalence of 3·2% and 1·4% respectively .…”

Section: Discussioncontrasting

confidence: 88%

First detection of human T‐lymphotropic virus in blood donors in Benin shows that testing is required to improve blood safety

Amoussa

Kashima²,

Djobessi³

et al. 2018

ISBT Science Series

View full text Add to dashboard Cite

Introduction Human T‐lymphotropic virus (HTLV) is a blood‐borne infection that can be transmitted via blood transfusion. Knowing that blood safety can improve blood transfusion to prevent dissemination of viral infections in medical facilities, there is no routine pre‐transfusion screening for HTLV in all blood banks in the Republic of Benin. This study aims to estimate the prevalence of HTLV infection in blood donors and describes the characteristics of positive donors. Methods A HTLV prevalence study was carried out by screening 2,035 samples by an enzyme‐linked immunoassay obtained from six blood banks located throughout the Republic of Benin. The PCR method was used to confirm and type all the ELISA reactive samples. Results and discussion Twelve subjects, all volunteer blood donors, were found with positive serology confirmed by a specific HTLV type 1 PCR assay, representing an overall seroprevalence of 0·59%. Furthermore, seven subjects were indeterminate for anti‐HTLV‐1/2 antibody and only one sample was confirmed positive for HTLV type 1 in a PCR reaction. These are the first cases of HTLV detection among blood donors in Benin Republic, whose blood was already transfused to recipients. This result emphasizes that HTLV needs to be considered as a Public Health issue in the Republic of Benin. Conclusion This study reports positive result of HTLV infection among blood donors in the blood banks of Benin Republic in West Africa and highlights the inclusion of screening tests and strategies to reduce its transmission.

show abstract

Section: Discussioncontrasting

confidence: 88%

First detection of human T‐lymphotropic virus in blood donors in Benin shows that testing is required to improve blood safety

Amoussa

Kashima²,

Djobessi³

et al. 2018

ISBT Science Series

View full text Add to dashboard Cite

show abstract

“…In Mali, Diarra et al . showed the prevalence of HTLV in multi‐transfused patients to be 2‐fold and 5·3‐fold higher (2·8% and 7·5%) in patients that received two and three blood transfusions, respectively, than in blood donors from the same region (1·4%).…”

Section: Discussionmentioning

confidence: 99%

The prevalence of human T‐lymphotropic virus type 1 & 2 (HTLV‐1/2) in South African blood donors

et al. 2019

View full text Add to dashboard Cite

Background and objectives Donated blood is not currently screened for human T‐cell lymphotropic virus (HTLV) in South Africa. Several small studies have detected HTLV‐1 in South Africa, but prevalence by geographic region or population group is unavailable. Materials and Methods We performed a large seroprevalence study of South African blood donors during 3 months in 2013. All geographic regions except the Western Cape were included, and Black and Coloured (local term for mixed race) donors were oversampled. Identity‐unlinked plasma samples were screened with the Abbott Prism HTLV‐1/2 assay, and repeatedly reactive samples were tested by the Inno‐LIA HTLV‐1/2 Score confirmatory assay. Odds ratios were calculated with multivariable logistic regression. Results Of 46 752 donors tested, 133 (0·28%) were initially reactive, 111 (0·24%) repeatedly reactive and 57 (0·12%) confirmed positive for HTLV‐1; none were HTLV‐2 positive. Prevalence was 0·062% weighted to annual blood donations but highly concentrated in the Black population group (OR = 20·24 CI: 2·77–147·88); higher in females than males (OR = 1·81 CI: 1·06–3·08); and in donors aged >50 years compared to ages 16–19 (OR = 6·4 CI: 2·95‐13·86). After controlling for age, sex and population group, there was no difference in prevalence between new and repeat blood donors or among geographic regions within South Africa. Conclusions We conclude that HTLV‐1 infection is widespread among the Black population of South Africa and its epidemiology is similar to other endemic areas. Because South Africa is increasing its recruitment of Black blood donors, the implications for blood screening require further consideration.

show abstract

“…Pocos estudios reportan resultados de sólo el tamizaje de HTLV 1/2, sin embargo, la prevalencia de tamizaje para HTLV 1/2 en Malí en 2011 fue de 1,4%, cifra que sobrepasa a la reportada en este estudio 21 . La importancia de las pruebas moleculares (PCR) en la confirmación de los resultados obtenidos en el tamizaje se evidencia en estudios que realizan esta prueba, como en el estudio hecho en Chile (Valdivia) en donde se reporta un 0,45% de positividad en el tamizaje para HTLV-1 (ELISA) y 0,24% en PCR 22 .…”

Section: Discussionunclassified

Seroprevalencia de HTLV1/2 en donantes de sangre, Boyacá - Colombia, 2011-2013

Medina-Alfonso

Forero-Pulido²,

Ramírez-Rueda

2016

Univ. Salud

View full text Add to dashboard Cite

Introducción: El virus linfotrópico humano de células T es un retrovirus, se encuentra asociado al riesgo de presentar dermatitis infecciosa, uveítis, polimiositis, artropatías, paraparesia espástica tropical, linfoma de células T del adulto y mieloma. Una de las vías de transmisión del HTLV 1/2 es la transfusión sanguínea de unidades que contienen el virus. Para evitar la transmisión de la infección por este retrovirus, el tamizaje en muestras de donantes de sangre ha sido obligatorio en muchos países y más recientemente en Colombia. Objetivo: Reportar la seroprevalencia de virus HTLV 1/ 2 en donantes de sangre de Boyacá-Colombia entre los años 2011 a 2013. Materiales y Métodos: Estudio descriptivo retrospectivo, en el que se estableció la seroprevalencia de HTLV 1/2 en 48.782 donantes de sangre captados en el departamento de Boyacá por tres bancos de sangre, utilizando la técnica quimioluminiscencia y como pruebas confirmatorias la técnica de InmunoBlot. Resultados: De los donantes tamizados, el 0,23% (113/48.782) fueron serorreactivos (positivos en la prueba de quimioluminiscencia), el 0,16% (78/48.782) fueron negativos, un 0,04% (21/48.782) fueron indeterminados y el 0,03% (14/48.782) fueron seropositivos por la técnica de InmunoBlot. Los donantes seropositivos correspondieron según el sexo a 0,016% (8/48.782) mujeres y 0,012% (6/48.782) a hombres. Conclusión: La prevalencia de HTLV 1/2 fue de 0,03%, similar a la de la mayoría de países que cuentan con reporte de esta determinación en donantes de sangre. Los datos generados en el estudio son los primeros reportados para Boyacá y aportan a la epidemiología del virus a nivel nacional. AbstractIntroduction: The Human T-cell lymphotropic virus is a retrovirus found to be associated with risks of infectious dermatitis, uveitis, polymyositis, arthropathies, tropical spastic paraparesis, myeloma and T-cell lymphoma. One of the means of transmission of HTLV 1/2 is the transfusion of blood units contaminated by the virus. To prevent this kind of transmission, blood donor screening has recently become a standard in Colombia and in many other countries. Objective: To report the seroprevalence of HTLV 1/2 virus in blood donors from Boyacá between 2011 and 2013. Materials and Methods: A retrospective descriptive study was performed, in which the seroprevalence of HTLV 1/2 was established in 48,782 blood donors from three blood banks in the department of Boyacá by using both chemiluminescence and western blot techniques. Results: From the screened donors, 0.23% (113 / 48,782) were seroreactive (chemiluminescence positive), 0.16% (78 / 48,782) were negative, 0.04% (21 / 48,782) were undefined and 0.03% (14 / 48,782) were seropositive by western blot. Concerning gender, seropositive donors were 0.016% (8/48,782) female and 0.012% (6 / 48,782) male. Conclusion: The prevalence of HTLV 1/2 was 0.03% which is similar to what has been found in most of the countries. The data generated in this study is the first of this kind available for Boyacá and will likely contribute to the virus epidemiology at the national level.

show abstract

Prevalence of HTLV-I virus in blood donors and transfusion in Mali: Implications for blood safety

Cited by 10 publications

References 17 publications

First detection of human T‐lymphotropic virus in blood donors in Benin shows that testing is required to improve blood safety

First detection of human T‐lymphotropic virus in blood donors in Benin shows that testing is required to improve blood safety

The prevalence of human T‐lymphotropic virus type 1 & 2 (HTLV‐1/2) in South African blood donors

Seroprevalencia de HTLV1/2 en donantes de sangre, Boyacá - Colombia, 2011-2013

Contact Info

Product

Resources

About